AC Immune Priced, Nasdaq: ACIU

Swiss biotech developing therapies for Alzheimer's, partnered with Genentech.

Industry: Health Care

Latest Trade: $11.00 -0.02 (-0.2%)

First Day Return: +42.4%

Return from IPO: +0.2%

Industry: Health Care

We are a clinical stage biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding. Misfolded proteins are generally recognized as the leading cause of neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease with common mechanisms and drug targets, such as Abeta, tau and alpha-synuclein. We believe that our large and diverse pipeline of seven therapeutic candidates, including four clinical-stage candidates and three diagnostic candidates, has the potential to drive a paradigm shift in the treatment of a broad spectrum of neurodegenerative and other diseases related to protein misfolding.
more less
IPO News for AC Immune
more
IPO Data
IPO File Date 05/31/2016
Offer Price $11.00
Price Range $11.00 - $13.00
Offer Shares (mm) 6.0
Deal Size ($mm) $66
IPO Data
IPO Date 09/22/2016
Offer Price $11.00
Price Range $11.00 - $13.00
Offer Shares (mm) 6.0
Deal Size ($mm) $66
Underwriters
more
Company Data
Headquarters Lausanne, Switzerland
Founded 2003
Employees 62
Website www.acimmune.com